The real-world safety of ticagrelor among older adults (above 75 years): a pharmacovigilance study from the FDA data

Back

ESC Professional Premium Access

The real-world safety of ticagrelor among older adults (above 75 years): a pharmacovigilance study from the FDA data

Session: Cardiovascular disease in the elderly

Topic: Cardiovascular Disease in the Elderly

Speaker: Doctor T. Lerman (Petah Tikva, IL)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Tsahi Tsvi Lerman

Rabin Medical Center, Petah Tikva (Israel)

0 follower

6 more presentations in this session

Effect of tranexamic acid in vascular surgery- a sub-study of the POISE-3 randomized clinical trial

Speaker: Doctor S. Ofori (Ontario, CA)

The long-term clinical impact of high-intensity statin therapy in older patients with acute myocardial infarction

Speaker: Doctor Y. Kwon (Daegu, KR)

Validation and development of a scoring system for comprehensively evaluating arterial damage in the elderly chinese

Speaker: Professor Y. Zhang (Shanghai, CN)

One- and five-year mortality according to first use of ticagrelor or clopidogrel at the acute stage of myocardial infarction in elderly patients: the FAST-MI 2015 registry

Speaker: Professor N. Danchin (Paris, FR)

Frailty and anticoagulant prescription in older hospitalized patients with atrial fibrillation: a multi-centred observational study

Speaker: Doctor T. Nguyen (Sydney, AU)

Access the full session

Cardiovascular disease in the elderly

Speakers: Doctor T. Lerman, Doctor S. Ofori, Doctor Y. Kwon, Professor Y. Zhang, Professor N. Danchin...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources